Since its creation, Vaxine has actively sought  collaborations and partnerships with university academics and small and large biotechnology and pharmaceutical companies. Through these partnerships Advax™ technology has been independently tested and  shown effective in a broad array of animal species and disease models. This has made Vaxine a research partner of more than 50  international companies and academic institutes.

Vaxine continues to actively look for partners in both the human and veterinary health industry who wish to use Advax™ adjuvant to enhance their vaccine immunogenicity and protection and/or for antigen sparing to reduce their vaccine cost of goods.